TORONTO– LSO today announced the recipients of its 2020 LSO Awards, recognizing outstanding individuals and companies contributing to the success of Ontario’s life sciences sector. The awards will be presented during LSO’s Celebration of Success Awards Dinner at Toronto’s Liberty Grand, February 26, 2020.
The 2020 awardees are as follows:
- Lifetime Achievement Award: Paul Lucas
- Community Service Award: Bruce Seet
- Volunteer Award: Ron Hosking
- Life Science Company of the Year: Deep Genomics
- LSO Leadership Award: Mary Jo Haddad
The LSO Awards are an important part of the organization’s mandate to advocate for Ontario’s life sciences sector, by celebrating the individuals and companies behind its success.
“This year’s award recipients have made outstanding contributions to the life sciences community in Ontario” said LSO President and CEO Dr. Jason Field. “Demonstrating leadership, dedication and innovation; all of these very deserving awardees have helped advance Ontario’s life sciences industry.”
Paul N. Lucas, former President & CEO, GlaxoSmithKline Inc
Lifetime Achievement Award
Mr. Paul Lucas is a highly respected leader in the Canadian Pharmaceutical and Life Science Industry. Starting his career with Eli Lilly and McNeil Pharmaceutical, he then joined GlaxoSmithKline where he served as President and CEO from 1994 until he retired in 2012.
Mr. Lucas served as Chair of the Board of Directors of TM Bioscience, Altimed Pharmaceuticals, and Life Sciences Ontario, was a member of the Board of Directors of Biochem Pharma, the Toronto Regional Research Alliance, Montreal InVivo, AllerGen, Ontario Genomics Institute and Select Therapeutics. He also served as Chair of the Board of Directors of Canada’s Research-Based Pharmaceutical Companies (Rx&D) for three terms. Currently Mr. Lucas is the Chair of the Board of Directors of EcoSynthetix Inc., Induran Ventures Inc., and VIVO Cannabis Inc and is also a member of the Board of RnA Diagnostics Inc.
Mr. Lucas was instrumental in setting up the MBiotech program at University of Toronto. He played a major role in attracting numerous investments in Life Sciences in Canada and in developing many Life Science organizations that continue to exist today.
In addition, he was a member of the Principal’s Advisory Council of the University of Toronto at Mississauga, and a member of the Board of Trustees of Queen’s University.
In 2010, he co-chaired, with John P Manley, P.C., O.C., the Coalition for Action on Innovation in Canada (CAIC) which created “An Action Plan for Prosperity” report.
Mr. Lucas received his BSc (Honours) in Biology and Chemistry from Queen’s University, and obtained his Chartered Directors designation (C.Dir) from the Directors College.
Mr. Lucas is the proud husband of Linda, father and father in law of Paula and Jory and Chad and Sara, and grand father of Ryla and Brody.
Bruce Seet, Director, Medical Affairs, Sanofi Pasteur
Community Service Award
Dr. Bruce Seet is a leader and advocate for broadening professional development opportunities for highly qualified personnel (HQP). Bruce founded and serves as the President/CEO of the Science to Business Network (www.s2bn.org), a national multi-chapter non-profit organization established in 2011 that connects stakeholders in industry, government and academia and provides professional development opportunities for HQP in Canada. As a Director, Medical Affairs at Sanofi Pasteur, he has been an advisor and mentor to more than a dozen pharmacy and HQP residents as part of the Leslie Dan School of Pharmacy Advanced Pharmacy Practice Experience, the University of Waterloo pharmacy co-op program and the Queen’s University’s Graduate Diploma in Pharmaceutical & Healthcare Management and Innovation. He also serves on the Research Management Committee as well as the HQP Development Committee for BioCanRx, an NCE that accelerates the development of cancer immunotherapeutics in Canada. Dr. Seet is an Adjunct Professor in the Department of Molecular Genetics at the University of Toronto where he teaches and supports graduate professional development in the department. Dr. Seet earned a B.Sc (Honours Physiology) and a Ph.D. (Microbiology and Immunology) from Western University, followed by a postdoctoral research fellowship at Mt. Sinai Hospital (Toronto). Bruce worked at GlaxoSmithKline (GSK) from 2006 to 2014 in a variety of roles. While at GSK, he completed his MBA at the Rotman School of Management (Toronto). In 2014, Bruce moved to Sanofi Pasteur where he continues to work as a Director, Medical Affairs.
Ronald G. Hosking, Chief Financial Officer, Plantform
Mr. Ron Hosking is a Chartered Professional Accountant with over 35 years of experience as a financial manager in the biotechnology and pharmaceutical industries. Mr. Hosking is a graduate from the University of Toronto with a Bachelor of Commerce in Finance.
Mr. Hosking has been a volunteer since the beginning of Life Sciences Ontario (then Toronto Biotechnology Initiative) back in 1989 as a part of Breakfast Forum and has been a committee member of the Annual LSO Golf Tournament since the first event in 2001. He is also a Director of the Toronto Chapter of Financial Executives International (FEI).
Mr. Hosking has been Chief Financial Officer at PlantForm Corporation since 2008 and is a member of the Board of Directors. PlantForm is a private Canadian company focusing on developing plant-based therapeutics. Prior to that, he was Vice-President Finance & Chief Financial Officer for PreMD Inc., a developer of point-of-care medical devices. He guided the company through seven public financings and onto the Toronto Stock Exchange (2000) and the AMEX (2002). Mr. Hosking also worked at Biomira Diagnostics as Vice President Finance and Ortho Diagnostics as Director of Finance. Mr. Hosking is a former Director and Chair of the Audit Committee of Cynapsus Therapeutics Inc. The Company was sold in October 2016.
Life Sciences Company of the Year
Deep Genomics is the leading artificial intelligence (AI) therapeutics company. We design, clinically evaluate, and market therapies that will have a transformative impact on the lives of individuals with rare genetic disorders. Currently, patients face a pharmaceutical industry in crisis: There are too many failures and successes take 15 years to come to fruition. At Deep Genomics we are revolutionizing drug development by using AI to predict scientific and clinical outcomes up front, increase success rates tenfold, and reduce development times to 5 years. Our AI platform combines deep learning, massive data generation, and advanced knowledge of genome biology to identify the genetic causes of disease and to guide the discovery and development of genetic therapies. We are developing therapies to address a range of metabolic, neurodegenerative and neuromuscular disorders, and we plan to enter the clinic in mid 2021.
Mary Jo Haddad, President, MJH & Associates
LSO Leadership Award
Ms. Mary Jo Haddad CM is recognized for her innovative leadership and commitment to life science as the past President and CEO of SickKids, a position she held for ten years following a leadership career in academic children’s healthcare in Canada and the US. A champion of research and innovation, she led the creation of the Peter Gilgan Center for Research and Learning, building capacity and commitment to discovery, research and commercialization. She served as the Founding Chair of MaRS Innovation (now TIAP) and through clarity of vision and tenacity, supported the success of an important collaboration in Toronto. She was Founding Director of the Vector Institute and has advised and supported many leaders in the life science ecosystem.
Mary Jo is currently President of MJH & Associates and Corporate Director of TD Bank Group and TELUS, where she serves as Chair of the Human Resources and Compensation Committee. She maintains a strong commitment to giving back as a mentor and leadership coach and as an advocate for children and youth through her volunteer work as past Director of the Board of Kids Health Links Foundation, SickKids capital campaign and Past Chair of Children First Canada.
Mary Jo was appointed Chancellor of the University of Windsor in May 2019.
Mary Jo holds a Masters of Health Science from the University of Toronto and a Bachelor of Science in Nursing from University of Windsor. She is a Member of the Order of Canada (2010) and received the Queen Elizabeth II Diamond Jubilee Medal (2014). Her contributions have been recognized with Honorary Doctor of Laws degrees from University of Windsor, Ryerson University and The University of Ontario Institute of Technology.
ABOUT LIFE SCIENCES ONTARIO (LSO)
Life Sciences Ontario (LSO) is a member-funded, not-for-profit organization with a legacy of more than 30 years advancing the success of Ontario’s life sciences sector. LSO collaborates with government, academia, industry, and other life sciences organizations in Ontario and across Canada to promote and encourage commercial success throughout the sector. The organization provides a wide range of networking and educational events and operates a mentorship program that is helping to develop highly skilled talent and build new business opportunities for the life sciences sector. In addition, LSO launched the Life Sciences Ontario Scholarship Program, the program awards students’ financial benefits and an opportunity to connect with a professional from the life sciences sector. LSO is an effective conduit for delivering policy options to governments, and its dedicated to promoting Ontario’s life sciences sector internationally. For more information, please visit [https://lifesciencesontario.ca].
Life Sciences Ontario